1
|
Ouoba S, Lingani M. A new tool for assessing hepatitis B treatment eligibility in Africa. Lancet Gastroenterol Hepatol 2024; 9:277-278. [PMID: 38367630 DOI: 10.1016/s2468-1253(24)00006-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Accepted: 01/19/2024] [Indexed: 02/19/2024]
Affiliation(s)
- Serge Ouoba
- Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro BP 18, Burkina Faso.
| | - Moussa Lingani
- Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro BP 18, Burkina Faso
| |
Collapse
|
2
|
Kramvis A, Lau DTY. Navigating TREAT-B in resource-limited settings. Lancet Glob Health 2024; 12:e8-e9. [PMID: 38097301 DOI: 10.1016/s2214-109x(23)00551-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 11/20/2023] [Indexed: 12/18/2023]
Affiliation(s)
- Anna Kramvis
- Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg 2193, South Africa.
| | - Daryl T Y Lau
- Division of Gastroenterology and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| |
Collapse
|